Zurueck zur Suche

Reporte zur Charge U029149

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

3Reporte angezeigt
0Todesfaelle
0Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
NH 1 OH 1 DE 1

VAERS 2507037

MERCK & CO. INC. · MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) · Charge U029149

mild
Staat
NH
Alter
5,0
Geschlecht
M
Eingang
08.11.2022
Impfdatum
21.06.2022
Beginn
22.06.2022
Tage bis Beginn
1,0
Dosis
2
Route/Site
- / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Injection site erythema Injection site pain Skin reaction

Symptomtext

Skin reaction with pain and redness to U Rt arm. Benadryl at night/apply ice/watch for worsening symptoms.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site erythema
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
Covid + 5/2/22
Vorgeschichte
N/A
Andere Medikamente
Flouride
Allergien
Amoxicillin
Vorherige Impfungen
-

VAERS 2623114

MERCK & CO. INC. · MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) · Charge U029149

gering
Staat
OH
Alter
5,0
Geschlecht
M
Eingang
28.04.2023
Impfdatum
02.05.2022
Beginn
05.05.2022
Tage bis Beginn
3,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Immunisation reaction

Symptomtext

Adverse effect of other vaccines and biological substances, initial encounter on 2022-05-05.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Immunisation reaction
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
Overweight; Encounter for routine child health examination NOS
Vorgeschichte
-
Andere Medikamente
None
Allergien
-
Vorherige Impfungen
-

VAERS 2249772

MERCK & CO. INC. · MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) · Charge U029149

gering
Staat
DE
Alter
1,0
Geschlecht
M
Eingang
25.04.2022
Impfdatum
01.04.2022
Beginn
01.04.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Inappropriate schedule of product administration No adverse event

Symptomtext

No additional AE details; VARIVAX and PROQUAD were inadvertently concomitantly administered to a 12 month old patient; This spontaneous report was received from a nurse referring to a 12-month-old male patient. The patient's medical history, concurrent conditions, and previous drug reactions or allergies were unknown by the reporter. Concomitant therapies included sterile diluent. On 01-APR-2022, the patient was inadvertently concomitantly administered measles, mumps, rubella and varicella (oka-merck) virus vaccine live recombinant human albumin (rha) (PROQUAD) 0.5 milliliters (mL) subcutaneously (lot number U029149 has been verified to be valid, expiration date reported and established as 16-MAR-2023), and varicella virus vaccine live (Oka/Merck) (VARIVAX) 0.5 milliliters (mL), once (route of administration was not reported; lot number U020240 has been verified to be valid, expiration date reported and established as 28-JUN-2023) (inappropriate schedule of product administration). Both vaccines were administered as prophylaxis. No additional adverse event reported (no adverse event).

Weitere VAERSDATA-Felder
Praegender Schweregrund
Inappropriate schedule of product administration
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
STERILE DILUENT
Allergien
-
Vorherige Impfungen
-